Alkermes plc. Accumulated Other Comprehensive Income
Alkermes plc. (ALKS) had Accumulated Other Comprehensive Income of -$2.92 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-07-28
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$2.92M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$2.91M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$2.10M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.06M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$2.92M 10-Q · filed 2026-07-28 |
| 2026-03-31 | -$2.91M 10-Q · filed 2026-05-05 |
| 2025-12-31 | -$2.10M 10-Q · filed 2026-07-28 |
| 2025-09-30 | -$1.06M 10-Q · filed 2025-10-28 |
| 2025-06-30 | -$1.40M 10-Q · filed 2025-07-29 |
| 2025-03-31 | -$1.46M 10-Q · filed 2025-05-01 |
| 2024-12-31 | -$1.97M 10-K · filed 2026-02-25 |
| 2024-09-30 | $425.00K 10-Q · filed 2024-10-24 |
| 2024-06-30 | -$3.59M 10-Q · filed 2024-07-24 |
| 2024-03-31 | -$3.60M 10-Q · filed 2024-05-01 |
| 2023-12-31 | -$3.11M 10-K · filed 2025-02-12 |
| 2023-09-30 | -$6.07M 10-Q · filed 2023-10-25 |
| 2023-06-30 | -$7.44M 10-Q · filed 2023-07-26 |
| 2023-03-31 | -$8.13M 10-Q · filed 2023-04-26 |
| 2022-12-31 | -$10.89M 10-K · filed 2024-02-21 |
| 2022-09-30 | -$12.84M 10-Q · filed 2022-11-02 |
| 2022-06-30 | -$10.49M 10-Q · filed 2022-07-27 |
| 2022-03-31 | -$8.23M 10-Q · filed 2022-04-27 |
| 2021-12-31 | -$3.72M 10-K · filed 2023-02-16 |
| 2021-09-30 | -$2.47M 10-Q · filed 2021-10-27 |
| 2021-06-30 | -$2.22M 10-Q · filed 2021-07-28 |
| 2021-03-31 | -$1.95M 10-Q · filed 2021-04-28 |
| 2020-12-31 | -$1.35M 10-K · filed 2022-02-16 |
| 2020-09-30 | -$760.00K 10-Q · filed 2020-10-29 |
| 2020-06-30 | -$101.00K 10-Q · filed 2020-07-29 |
| 2020-03-31 | -$1.50M 10-Q · filed 2020-04-29 |
| 2019-12-31 | -$1.82M 10-K · filed 2021-02-11 |
| 2019-09-30 | -$1.64M 10-Q · filed 2019-10-23 |
| 2019-06-30 | -$1.61M 10-Q · filed 2019-07-25 |
| 2019-03-31 | -$2.51M 10-Q · filed 2019-04-25 |
| 2018-12-31 | -$3.28M 10-K · filed 2020-02-13 |
| 2018-09-30 | -$3.67M 10-Q · filed 2018-10-23 |
| 2018-06-30 | -$3.98M 10-Q · filed 2018-07-26 |
| 2018-03-31 | -$4.13M 10-Q · filed 2018-04-26 |
| 2017-12-31 | -$3.79M 10-K · filed 2019-02-15 |
| 2017-09-30 | -$3.25M 10-Q · filed 2017-10-26 |
| 2017-06-30 | -$3.33M 10-Q · filed 2017-07-27 |
| 2017-03-31 | -$3.20M 10-Q · filed 2017-04-27 |
| 2016-12-31 | -$3.27M 10-K · filed 2018-02-16 |
| 2016-09-30 | -$2.81M 10-Q · filed 2016-11-02 |
| 2016-06-30 | -$2.55M 10-Q · filed 2016-07-28 |
| 2016-03-31 | -$2.86M 10-Q · filed 2016-04-28 |
| 2015-12-31 | -$3.79M 10-K · filed 2017-02-17 |
| 2015-09-30 | -$2.71M 10-Q · filed 2015-10-29 |
| 2015-06-30 | -$2.73M 10-Q · filed 2015-07-30 |
| 2015-03-31 | -$2.65M 10-Q · filed 2015-04-30 |
| 2014-12-31 | -$3.14M 10-K · filed 2016-02-25 |
| 2014-09-30 | -$2.87M 10-Q · filed 2014-10-29 |
| 2014-06-30 | -$2.71M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $8.04M 10-Q · filed 2014-04-30 |
| 2013-12-31 | $10.57M 10-K · filed 2015-02-24 |
| 2013-09-30 | $5.58M 10-Q · filed 2013-10-31 |
| 2013-06-30 | -$2.92M 10-Q · filed 2013-07-25 |
| 2013-03-31 | -$2.52M 10-KT · filed 2014-02-27 |
| 2012-12-31 | -$2.66M 10-Q · filed 2013-01-31 |
| 2012-09-30 | -$2.79M 10-Q · filed 2012-11-01 |
| 2012-06-30 | -$2.93M 10-Q · filed 2012-07-26 |
| 2012-03-31 | -$2.71M 10-K · filed 2013-05-23 |
| 2011-12-31 | -$2.92M 10-Q · filed 2012-02-02 |
| 2011-09-30 | -$2.92M 10-Q · filed 2011-11-03 |
| 2011-03-31 | -$3.01M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |